ImmunOs Therapeutics AG Raises CHF 15M in Series A Financing, Co-led by Pfizer Ventures and BioMedPartners, to Advance a Novel Immunotherapy Agent For Cancer Into Human Trials
10.12.2019 11:00:00 EET | Business Wire | Press release
ImmunOs Therapeutics AG, a Swiss bio-technology company and leading developer of a next generation innate immunity focused immunotherapy platform for cancer, announced today the closing of a Series A financing of CHF 15 million. The round was co-led by the Basel life sciences venture capital firm BioMedPartners and Pfizer Ventures, the venture capital arm of Pfizer Inc. (NYSE: PFE), with the participation of Redalpine, Schroder Adveq, Wille Finance AG, BERNINA BioInvest Ltd alongside new private and existing investors. The financing will be used to complete the first-in-human trials with the company’s lead agent, iosH2, a potential new cancer treatment for both solid and liquid tumors. The funding will also be used to broaden the company’s novel immunotherapy iosH platform by advancing additional preclinical programs focusing on both cancer and auto-immunity.
“Recent advances in the understanding of the innate immune system’s role in cancer provide a unique opportunity for ImmunOs Therapeutics and our partners. We value the ongoing support of all the current investors and welcome all the Series A round participants, specifically Pfizer Ventures and BioMedPartners, both of whom have demonstrated a strong commitment to the oncology field,” said Sean R. Smith, CEO of ImmunOs Therapeutics AG.
Dr. Osiris Marroquin Belaunzaran, CSO and co-founder, added: “It is with great pleasure to see that our early research based on HLA open conformer modulation of immune cells is advancing toward a clinical drug candidate for human studies. Targeting the innate immune system to modulate the tumor microenvironment has been a key strategy for ImmunOs, and together with foundational approaches targeting the adaptive immune system such as PD-1 antibodies, we aim to produce a strong therapeutic benefit in difficult-to-treat cancer indications."
In conjunction with the financing, ImmunOs Therapeutics has expanded its Board of Directors to include four new members: Dr. Markus Hosang of BioMedPartners; Dr. Michael Baran of Pfizer Inc.; Dr. Reinhard Ambros, former head Novartis Venture Fund; and Dr. Daniel Vasella, former Chairman and CEO Novartis.
Dr. Markus Hosang noted: “At BioMedPartners, we have over the last 15 years very successfully invested in and brought forward several innovative early-stage cancer companies. We got particularly attracted by ImmunOs and its novel approach that also adds to existing treatment modalities and thus has the potential to provide novel medicines to cancer patients who do not obtain a long-term benefit from current therapies.”
Dr. Michael Baran added: “Advances in understanding the role of the innate immune system is opening up opportunities to expand the potential of cancer immunotherapy. Pfizer Ventures is enthusiastic to support this emerging area through our investment in ImmunOs.”
About ImmunOs Therapeutics AG:
ImmunOs Therapeutics AG is a biotechnology company active in the discovery and development of the next generation of novel human immunomodulatory proteins focused on innate immunity. Originally a spin-off company of the University of Zurich and the University of Basel, our mission is to develop novel therapeutics that will improve the lives of patients with serious disease.
ImmunOs Therapeutics AG lead program is a next generation, novel platform of multitasking biologics targeting diverse immunoregulatory receptors that activate anti-tumor responses built upon years of research and development. ImmunOs proteins work directly on the innate immune system. (For more information, please visit www.immunostherapeutics.com)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191210005042/en/
Contact information
Investor Relations
Wagistrasse 14
8952 Schlieren (Zurich Area), Switzerland
info@immunostherapeutics.com
International Media Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info@akampion.com
Tel. +49 40 88 16 59 64 or +49 30 23 63 27 68
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIQ Named 2026 Retail & Consumer Goods Snowflake Product Partner of the Year3.6.2026 14:00:00 EEST | Press release
NielsenIQ (NYSE:NIQ) today announced that it has been named the 2026 Retail & Consumer Goods Snowflake Product Partner of the Year award recipient by Snowflake, the AI Data Cloud company. NIQ was recognized for its achievements at Snowflake’s annual user conference, Snowflake Summit 26, for delivering scalable, cloud-native solutions on Snowflake that enable retailers, brands, and media partners to securely enrich data, measure performance, and unlock more precise, actionable commerce intelligence. Through Snowflake’s AI Data Cloud, NIQ helps joint customers collaborate across organizations, activate high-value data assets, and power advanced measurement while maintaining strong governance and data privacy controls. By embedding NIQ’s AI-driven data, models, and harmonization capabilities within Snowflake, customers can unify fragmented datasets into a trusted, scalable foundation for AI. This makes it easier to operationalize AI-powered decision-making and move faster from insight to
Aircall Acquires Piper AI to Turn Customer Conversations Into Revenue Action3.6.2026 13:03:00 EEST | Press release
Aircall, the AI-powered customer communications platform trusted by more than 23,000 businesses worldwide, today announced the acquisition of Piper AI, a revenue intelligence and agentic sales orchestration company. With Piper, Aircall extends its platform beyond the conversation itself—giving sales teams the tools to automatically act on every interaction, across every channel, from first touch to closed deal. Aircall already powers the conversations that drive revenue. Its platform unifies voice, SMS, and WhatsApp into a single workspace, with its AI Assist suite guiding sales reps before each call with account briefs, coaching them live with real-time playbooks and objection prompts, and automatically logging calls, generating summaries, and drafting follow-ups when the conversation ends. Deals don't close on a single call. They move—or stall—across emails, video meetings, follow-up threads, and multi-stakeholder conversations that unfold over weeks. Most of that activity is invisib
Rezon Bio Appoints Dr. Ralf Otto as Chief Operating Officer to Support Next Phase of Growth and Operational Expansion3.6.2026 13:01:00 EEST | Press release
Rezon Bio, a science-driven European biologics contract development and manufacturing organization (CDMO), today announced the appointment of Dr. Ralf Otto, as Chief Operating Officer (COO) effective June 1, 2026. In his role, Ralf Otto, PhD, will be responsible for the operational areas of clinical and commercial cGMP manufacturing, development, quality, engineering and business operations across Rezon Bio’s integrated end-to-end CDMO platform. His appointment comes as Rezon Bio enters its next phase of growth, focused on broadening its service offering, expanding its global client base, and improving access to biosimilars and novel biologics through operational excellence, scalability, and enhanced price competitiveness. Ralf Otto, PhD, brings more than 25 years of international leadership experience across the CDMO and biopharmaceutical industry, with extensive expertise in biologics development, clinical and commercial cGMP manufacturing, technology transfer, manufacturing scale-up
Danube Properties Expands UK Presence with New London Office, Eyes Wider European Growth3.6.2026 12:34:00 EEST | Press release
Danube Properties, one of the UAE’s leading real estate developers, is set to strengthen its international presence with the launch of its new sales office in Central London. Located at 44 Brompton Road, Knightsbridge, SW3 1BW, the new office marks another milestone in the company’s growing expansion across the United Kingdom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260530149191/en/ Atif Farid, Head Business Development (UK); Rizwan Sajan, Founder and Chairman of Danube Group; and Adel Sajan, Managing Director of Danube Group, at the launch of Danube Properties' new sales office in Central London. (Photo: AETOSWire) The opening follows the successful launch of Danube Properties’ first UK office in Harrow two years ago, which established a strong connection with investors and homebuyers seeking premium Dubai real estate opportunities. Building on this momentum, the new Knightsbridge office aims to provide enhanced acce
Sensofusion Introduces its Aerospace Unit: Swift Surveillance Aircraft and Fennec Satellites3.6.2026 12:30:00 EEST | Press release
Finnish defence technology company Sensofusion Oy is expanding its operations from the ground to the air and into Earth orbit. As of today, the company's aviation and space business will operate under the name Sensofusion Aerospace.The unit's ongoing product development projects are the Sensofusion Swift surveillance aircraft and the company's first two satellite missions, Fennec-1 and Fennec-2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603447178/en/ With the Fennec-satellite program, Sensofusion's sensing capability extends into Earth orbit. Sensofusion Swift is a type-certified general aviation aircraft with integrated signals intelligence capability, radar and other advanced sensors. Unlike unmanned systems, Swift can operate in peacetime airspace near airports and population centres without separate exemptions. Sensofusion Swift is both an aircraft and a drone. It can be procured and operated either as a crewed g
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom